-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 17, 2022, Remix Therapeutics announced an R&D collaboration with Janssen, a subsidiary of Johnson & Johnson, to use Remix's REMaster drug discovery platform to develop small molecule therapeutics that modulate RNA processing
Traditional drug development treats diseases by regulating the activity of proteins or enzymes related to diseases.
Image source: Remix's official website
Remix employs a novel strategy to treat diseases by reprogramming RNA processing
Image source: Remix's official website
Under the terms of the agreement, Remix will receive up to $45 million in upfront payments and research funding, and may receive preclinical, clinical, and commercialization milestone payments, as well as future tiered royalties on any resulting products, the potential total amount may be over $1 billion
Dr.
English original link: https:// rna-processing/
https://